Introduction
============

Budd-Chiari syndrome (BCS) is a rare disease ([@b1-mmr-16-06-8011]), which occurs in 1/100,000 of the general population worldwide ([@b2-mmr-16-06-8011]). BCS is characterized by the occlusion or obstruction of the hepatic venous outflow ([@b3-mmr-16-06-8011]), which located at the hepatic veins or on the suprahepatic portion of inferior vena cava ([@b4-mmr-16-06-8011]). The hepatic veno-occlusive disease as well as the obstruction induced by congestive heart failure is excluded from this definition. The main symptoms of the BCS are abdominal pain, hepatomegaly and ascites ([@b5-mmr-16-06-8011]).

BCS is a multifactorial disease and its etiology and underlying mechanism is not fully understood. However, a hypercoagulable state and thrombosis with increased blood viscosity are suspected to be the most common pathophysiological mechanism ([@b6-mmr-16-06-8011]). Myeloproliferative disorders (MPDs) including polycythemia vera, essential thrombocythemia and paroxysmal nocturnal hemoglobinemia are prothrombotic disorders ([@b4-mmr-16-06-8011]) that induce a hypercoagulable state ([@b7-mmr-16-06-8011],[@b8-mmr-16-06-8011]), which are the major causes of BCS, and account for 40% of BCS cases ([@b9-mmr-16-06-8011]). In addition, antiphospholipid syndrome, hyperhomocysteinemia, pregnancy, the use of oral contraceptive pills and deficiency in antithrombin III proteins C and S, may also increase the risk of BCS ([@b10-mmr-16-06-8011],[@b11-mmr-16-06-8011]). Several gene mutations including the JAK2 V617F, and the factor V Leiden are also associated with BCS ([@b12-mmr-16-06-8011],[@b13-mmr-16-06-8011]).

The 1-year spontaneous mortality rate of BCS is up to 70% ([@b14-mmr-16-06-8011]). Since there is a lack of accurate and effective diagnosis and treatment in the early stages of BCS, the mortality rate still remains high, despite the current surgical approach ([@b14-mmr-16-06-8011]). Therefore, it is crucial to develop a novel strategy for an accurate and sensitive diagnosis, and an effective therapy.

Differentially expressed genes (DEGs) in BCS patients compared with the normal controls can make a contribution to discovering the pathological progress and develop novel diagnostic biomarkers for BCS. High-throughput technologies which generate millions of reads in a short time and at a low cost were developed rapidly in recent years ([@b15-mmr-16-06-8011]). RNA deep-sequencing (RNA-seq) can sequence cDNA and determine the RNA content in a sample by using next-generation sequencing technologies ([@b16-mmr-16-06-8011]). RNA-seq is a powerful method to decipher global gene expression patterns and identify DEGs which have been used in many research areas ([@b17-mmr-16-06-8011]) while this technique has not been performed to analyze and characterize the BCS transcriptome.

In the present study, RNA-seq was used to identify DEGs in the BCS and functional annotation analysis and Protein-Protein Interaction (PPI) networks construction were performed to find the BCS-associated genes and pathways. This may provide clues to pathological mechanisms, diagnostic and therapeutic strategy for BCS.

Materials and methods
=====================

### Patients

Blood samples were obtained from three patients (patients 1--3) who were diagnosed with BCS, and from three healthy individuals (normal controls; NC 1--3). Patient 1 was male, 31 years old, and had been admitted to the hospital because of dizziness and fatigue for 50 days and platelet reduction for 20 days and was diagnosed with BCS (occlusion of inferior vena cava located above the hepatic vein with many collateral circulations) with splenomegaly and anemia. Patient 2 was female, 49 years old, and was hospitalized for occasional swelling of the upper abdomen, and was diagnosed with BCS (occlusion of inferior vena cava located above the hepatic vein with many collateral circulations). Patient 3 was male, 68 years old, and had been admitted to the hospital because of swelling of lower limbs and infections of lower limb ulcerations for 1 year, and was diagnosed with BCS (occlusion of inferior vena cava located near right atrium with many collateral circulations) with infections of lower limbs ulcerations, rheumatoid arthritis and chronic bronchitis. None of these three patients had prior history of medication and family history. All the participants submitted the written informed consent and the protocol was approved by the ethical committee of Shandong Jining No. 1 People\'s Hospital, Shandong, China.

### RNA isolation and sequencing

According to the manufacturer\'s protocol, total RNA was isolated from blood samples using TRIzol (Invitrogen; Thermo Fisher Scientific Inc., Waltham, MA, USA). An RNeasy mini kit (Qiagen Inc., Valencia, CA, USA) was used to purify the total RNA. The quantity and integrity of purified RNA was checked using a Nanodrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Inc.) and an Agilent 2100 Bioanalyzer. With a TruSeq RNA library preparation kit (Illumina Inc., San Diego, CA, USA), messenger RNA was purified from the samples (RIN\>7), through oligo-d(T) probes for polyA selection. qPCR was performed using a QIAquick PCR kit (Qiagen Inc.) and the RNA-seq library was constructed. Sequencing was performed on a HiSeqTM 2500 platform (Illumina Inc.).

### Identification of DEGs

By using FastQC (version 0.11.4; Babraham Institute, Cambridge, UK), the quality control of fastq data was performed (Read QC). To obtain the high quality clean data, Cutadapt version 1.9.1 (<http://cutadapt.readthedocs.io/en/stable/changes.html#v1-9-1-2015-12-02>) was used to remove low quality sequences, including ambiguous nucleotides and adaptor sequences. The alignment between the cleaned sequencing reads were aligned to the human genome (GRCh38.p7 assembly) by Tophat version 2.1.1 (<http://ccb.jhu.edu/software/tophat/index.shtml>) using the genome human University of California Santa Cruz reference annotation ([www.ucsc.edu/](www.ucsc.edu/)). Cuffdiff ([cole-trapnell-lab.github.io/cufflinks/cuffdiff/index.html](cole-trapnell-lab.github.io/cufflinks/cuffdiff/index.html)) was used to assemble transcript and determine transcript abundance. Fragments per kilobase of exon per million fragments were mapped to determine the transcription abundancy of each gene.

### Functional annotation

To further investigate the biological function of DEGs, Gene Ontology (GO) enrichment analysis, using the 'Biological Process and Molecular Function' tools, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed by using the online software GeneCodis (genecodis.cnb.csic.es/analysis). A false discovery rate (FDR)\<0.05 was defined as the criteria for statistical significance.

### PPI network construction

The PPI network makes a contribution to discovering the disease-associated pathways and reforming the strategy for drug design, which is superior to the simple activation and inhibition analysis of a single protein. In the present study, the top 20 upregulated and downregulated DEGs were used to construct the PPI network by using Biological General Repository for Interaction Datasets (BioGRID) ([thebiogrid.org/](thebiogrid.org/)) and Cytoscape ([www.cytoscape.org/](www.cytoscape.org/)). Proteins were represented using nodes and the interactions between two proteins were represented by edges.

### Statistical analysis

Student\'s t-test was performed to identify the differentially expressed genes (DEGs). P\<0.05 and abs (count_1-count_2)\>100 was considered to indicate a statistically significant difference.

Results
=======

### RNA-sequencing and identification of DEGs

Blood samples from three BCS patients and three healthy controls were subjected to RNA sequencing. In total, 2.73×10^7^, 2.77×10^7^ and 2.73×10^7^ sequencing reads from BCS blood, and 2.74×10^7^, 2.68×10^7^ and 2.69×10^7^ reads from healthy blood respectively, were generated. In addition, 90.2, 89.6 and 91.3% reads from BCS blood, and 87.7, 89 and 89.8% reads from healthy blood, respectively, were mapped ([Table I](#tI-mmr-16-06-8011){ref-type="table"}).

In total, 405 DEGs were identified, including 317 upregulated and 88 downregulated DEGs with P\<0.05 and abs (count_1-count_2)\>100. The top 20 upregulated and downregulated DEGs are displayed in [Table II](#tII-mmr-16-06-8011){ref-type="table"}. The heat-map of the top 100 DEGs is illustrated in [Fig. 1](#f1-mmr-16-06-8011){ref-type="fig"}.

### Functional annotation

Following the GO enrichment analysis, viral transcription (FDR=1.86E-20), translational elongation (FDR=2.28E-20), protein binding (FDR=7.42E-31), structural constituent of ribosome (FDR=7.52E-16), cytosol (FDR=2.02E-33) and cytoplasm (FDR=2.38E-30) were the most significantly enriched GO terms of DEGs in the BCS samples ([Fig. 2](#f2-mmr-16-06-8011){ref-type="fig"}). KEGG enrichment analysis ([Fig. 3](#f3-mmr-16-06-8011){ref-type="fig"} and [Table III](#tIII-mmr-16-06-8011){ref-type="table"}) indicated that ribosome (FDR=1.25E-17), phagosome (FDR=0.000204) and lysosome (FDR=0.000368) were the most significantly enriched pathways in the BCS samples. The proteasome (FDR=0.002124) was another significantly enriched pathway in BCS, including DEGs such as the proteasome subunit β type (PSMB) −2 and −10, proteasome subunit α type-6 (PSMA6), proteasome inhibitor PI31 subunit (PSMF1) and 26S proteasome non-ATPase regulatory subunit 2 (PSMD2).

### PPI network

The PPI network of 30 DEGs (18 upregulated and 12 downregulated DEGs) were constructed including 685 nodes and 747 edges ([Fig. 4](#f4-mmr-16-06-8011){ref-type="fig"}). According to the PPI network, synuclein α (SNCA; degree=177), tubulin β-2A (TUBB2A; degree=89) and zinc finger protein GFI-1b (GFI1B; degree=76) were the three most significant hub proteins.

Discussion
==========

In order to elucidate the pathogenesis of BCS at the molecular level, RNA-sequencing was performed to analyze the transcriptome of BCS patients compared with the healthy controls. A total of 405 DEGs including 317 upregulated and 88 downregulated DEGs, were identified.

Since myeloproliferative diseases (MPDs) are a leading cause for BCS ([@b9-mmr-16-06-8011]) genes associated with MPDs may serve an important role in BCS.

A total of three MPDs-associated DEGs were identified. Secreted protein acidic and cysteine rich (SPARC) encodes a matrix-associated protein, which is involved with the maintenance and restoration of tissue homeostasis ([@b18-mmr-16-06-8011]). Recently, SPARC was reported to serve an essential role in bone marrow stromal response to myeloproliferation. Deficiency of SPARC can induce myelofibrosis (MF), can suppress the activity in primary MF and enhance the myeloproliferative response to thrombopoietin ([@b19-mmr-16-06-8011],[@b20-mmr-16-06-8011]). Hence, SPAR1 is a key gene which is associated with MPDs. In the present study, SPACR was upregulated in the BCS patients compared with the controls, confirming that SPACR may serve a key role in BCS as well as in MPDs. Lipocalin-2 (LCN2) is an inflammatory cytokine which is localized to myeloid cells within MF marrow cells ([@b21-mmr-16-06-8011]). LCN2 was reported to be involved in the pathophysiological progress of MPDs ([@b9-mmr-16-06-8011]). Compared with the controls, upregulated LCN2 was detected in the plasma of multiple MPDs patients including primary MF, PV-MF, and ET-MF patients ([@b9-mmr-16-06-8011]). According to the present study, LCN2 was upregulated in the BCS patients as well. Another MPDs-associated DEG identified, was interferon-inducible gene 27 (IFI27). IFI27 was reported to be upregulated in the patients with MPDs ([@b22-mmr-16-06-8011]), which was downregulated in BCS patients in the present study, but requires further investigation. Therefore, it can be speculated that dysregulation of LCN2 and IFI27 may also serve an essential role in BCS affecting the progress of MPDs.

Based on the PPI network, three hub genes including *SNCA*, *TUBB2A* and *GFI1B* were identified. Among them, the *GFI1B* gene is a member of growth factor independence 1 gene family which is expressed in hematopoietic stem cells and myeloid progenitors ([@b23-mmr-16-06-8011]). Previous studies have speculated that GFI1B may serve an important role in MPDs too ([@b9-mmr-16-06-8011]). Because GFI1B is another DEG which identified among the top 20 upregulated DEGs it can be concluded that it may also be involved in the BCS possibly through its role function in MPDs.

According to the KEGG enrichment analysis, proteasome was a significantly enriched pathway in BCS. Proteasome was reported to support stimulated platelet function and thrombosis, and its inhibition can induce a hypothrombotic state and reduce thrombosis ([@b10-mmr-16-06-8011]). Since the hypothrombotic state is a major mechanism of BCS, it can be concluded that proteasome may serve an essential role in BCS by regulating thrombosis, and the proteasome-associated DEGs including PSMB10, PSMA6, PSMF1, PSMB2 and PSMD2 may be closely associated with the pathological process of BCS.

In conclusion, several DEGs were identified in the BCS samples using RNA-seq, including SPARC, LCN2, IFI27 and GFI1B. Proteasome-associated DEGs may be involved in BCS through regulating the thrombosis. The results of the present study may provide a contribution to uncovering the underlying pathogenesis of BCS and to developing novel strategies for its diagnosis and treatment.

The present study was supported by the Study of the Coagulation Function and Related Genes for Budd-Chiari syndrome in Jining (grant no. 2014jnwk10).
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###### 

RNA sequencing results.

  Sample   Clean reads   Clean bases     Read length (bp)   Q20 (%)       GC (%)   Mapped (%)
  -------- ------------- --------------- ------------------ ------------- -------- ------------
  A1       27,352,176    4,102,826,400   150                98.86;96.96   59.11    90.2
  A2       27,749,880    4,162,482,000   150                98.85;97.35   58.16    89.6
  A3       27,330,906    4,099,635,900   150                98.89;97.01   61.04    91.3
  B1       27,420,208    4,113,031,200   150                98.71;96.98   55.60    87.7
  B2       26,909,146    4,036,371,900   150                98.72;97.17   55.76    89
  B3       26,754,504    4,013,175,600   150                98.82;97.02   57.73    89.8

Q20, the number of nucleotide with quality \>20/nucleotide (paired-end reads: Clean read 1, read 2); GC, Guanine Cytosine number/nucleotide (paired-end reads: Clean read 1 read 2).

###### 

Top 20 upregulated and downregulated differentially expressed genes in the BCS samples.

  Gene ID     Gene           NC count   BCS count   log2FC     P-value
  ----------- -------------- ---------- ----------- ---------- ------------
  60675       PROK2          521.102    178.57      −1.44204   5.00×10^5^
  387066      SNHG5          435.639    148.469     −1.62065   5.00×10^5^
  9172        MYOM2          472.403    32.4931     −3.86276   5.00×10^5^
  6231        RPS26          2,135.57   583.471     −1.90969   5.00×10^5^
  6235        RPS29          1,462.01   820.173     −1.19722   5.00×10^5^
  9381        OTOF           161.644    41.5735     −2.01754   5.00×10^5^
  133         ADM            363.37     174.728     −1.08298   0.0001
  3429        IFI27          369.492    120.606     −1.81854   0.0001
  6227        RPS21          2,030.92   1,169.11    −1.0646    0.00015
  10578       GNLY           1,866.86   911.448     −1.09558   0.00015
  254948      RPL9P8         629.595    300.206     −1.04615   0.0002
  400499      LOC400499      674.824    290.442     −1.3079    0.00025
  84525       HOPX           194.717    92.5097     −1.02509   0.0003
  55007       FAM118A        305.302    147.011     −1.04756   0.00035
  105378415   LOC105378415   214.944    95.7043     −1.01748   0.0004
  3759        KCNJ2          333.635    163.374     −0.89589   0.00055
  54541       DDIT4          510.538    284.93      −0.88093   0.00065
  83999       KREMEN1        286.922    149.081     −0.94533   0.0009
  60674       GAS5           259.73     133.546     −0.9557    0.00095
  6170        RPL39          1,460.23   905.571     −0.86872   0.001
  6622        SNCA           565.441    2,083.61    1.94496    5.00×10^5^
  10098       TSPAN5         137.195    527.282     2.02604    5.00×10^5^
  10158       PDZK1IP1       375.33     1,593.21    2.02767    5.00×10^5^
  6886        TAL1           88.6704    284.49      1.74036    5.00×10^5^
  6678        SPARC          297.068    709.309     1.31365    5.00×10^5^
  7280        TUBB2A         22.716     543.469     4.50119    5.00×10^5^
  2766        GMPR           164.324    1,066.46    2.69842    5.00×10^5^
  3118        HLA-DQA2       37.4776    192.71      2.3648     5.00×10^5^
  221895      JAZF1          127.371    274.85      1.20758    5.00×10^5^
  669         BPGM           101.964    238.092     1.33635    5.00×10^5^
  28959       TMEM176B       481.731    1,453.35    1.57701    5.00×10^5^
  2039        DMTN           1,493.17   5,665.35    1.86345    5.00×10^5^
  286         ANK1           72.7907    251.764     1.73898    5.00×10^5^
  759         CA1            59.5486    213.457     1.92874    5.00×10^5^
  54855       FAM46C         148.663    514.282     1.91142    5.00×10^5^
  573         BAG1           1,319.88   4,566.92    1.85414    5.00×10^5^
  25853       DCAF12         628.567    2,552.27    2.10923    5.00×10^5^
  3934        LCN2           20.686     141.522     2.75439    5.00×10^5^
  8328        GFI1B          58.8981    188.993     1.65276    5.00×10^5^
  10133       OPTN           604.938    1,309.79    1.19751    5.00×10^5^

BCS, Budd-Chiari syndrome. NC count, normal control counts in samples; BCS count, read-counts in samples of Budd-Chiari syndrome.

###### 

Most enriched pathways identified in the BCS samples.

  KEGG ID    KEGG term                                     No. of genes   FDR        Gene list
  ---------- --------------------------------------------- -------------- ---------- -------------------------------------------------------------------------------------------------------------------------------------
  hsa03010   Ribosome                                      19             1.25E-17   RPS15A, RPS26, RPS3A, RPS25, RPL17, RPS7, RPL30, RPS21, RPL31, RPL35, RPS28, RPL26, RPL39, RPL23, RPS29, RPS27, RPL34, RPS24, RPL27
  hsa04145   Phagosome                                     10             0.000204   HLA-DMA, NCF1, ATP6V0A1, TUBB2A, DYNC1H1, RILP, CYBB, ATP6V0C, FCGR1A, HLA-DQB1
  hsa04142   Lysosome                                        9            0.000368   MCOLN1, GM2A, TPP1, ATP6V0A1, GUSB, DNASE2, SORT1, ATP6V0C, AP1B1
  hsa04380   Osteoclast differentiation                      9            0.000384   NCF1, PLCG2, RELB, LILRB1, SOCS3, CSF1R, CYBB, LILRB4, FCGR1A
  hsa03050   Proteasome                                      5            0.002124   PSMB10, PSMA6, PSMF1, PSMB2, PSMD2
  hsa00860   Porphyrin and chlorophyll metabolism            5            0.002248   FECH, GUSB, BLVRB, HMBS, ALAS2
  hsa00030   Pentose phosphate pathway                       4            0.00423    FBP1, GPI, G6PD, PGD
  hsa04640   Hematopoietic cell lineage                      6            0.005515   CD22, GP1BB, ITGA2B, CSF1R, FCGR1A, CD2
  hsa00520   Amino sugar and nucleotide sugar metabolism     4            0.024957   HK1, GPI, TSTA3, RENBP
  hsa05144   Malaria                                         4            0.024957   HBD, KLRK1, GYPC, LRP1
  hsa05150   Staphylococcus aureus infection                 4            0.02602    HLA-DMA, FPR2, FCGR1A, HLA-DQB1
  hsa04966   Collecting duct acid secretion                  3            0.031755   SLC4A1, ATP6V0A1, ATP6V0C
  hsa05110   Vibrio cholerae infection                       4            0.032999   PLCG2, ATP6V0A1, ATP6V0C, GNAS
  hsa04910   Insulin signaling pathway                       6            0.034042   HK1, FBP1, RPTOR, SOCS3, PPP1R3B, INPP5K
  hsa04666   Fc gamma R-mediated phagocytosis                5            0.035841   NCF1, PLCG2, GSN, WASF2, FCGR1A
  hsa00010   Glycolysis/Gluconeogenesis                      4            0.043693   HK1, FBP1, GPI, BPGM

BCS, Budd-Chiari syndrome; KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.
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